FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775990711> ?p ?o ?g. }

• W2775990711 endingPage "1602" @default.
• W2775990711 startingPage "1594" @default.
• W2775990711 abstract "Purpose Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors. We hypothesized that a combination of selective ATR inhibitor M6620 (previously VX-970) and topotecan, a selective TOP1 inhibitor, would be tolerable and active, particularly in tumors with high replicative stress. Patients and Methods This phase I study tested the combination of M6620 and topotecan in 3-week cycles using 3 + 3 dose escalation. The primary end point was the identification of the maximum tolerated dose of the combination. Efficacy and pharmacodynamics were secondary end points. Results Between September 2016 and February 2017, 21 patients enrolled. The combination was well tolerated, which allowed for dose escalation to the highest planned dose level (topotecan 1.25 mg/m 2 , days 1 to 5; M6620 210 mg/m 2 , days 2 and 5). One of six patients at this dose level experienced grade 4 thrombocytopenia that required transfusion, a dose-limiting toxicity. Most common treatment-related grade 3 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%); and thrombocytopenia (10%). Two partial responses (≥ 18 months, ≥ 7 months) and seven stable disease responses ≥ 3 months (median, 9 months; range, 3 to 12 months) were seen. Three of five patients with small-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or prolonged stable disease (10, ≥ 6, and ≥ 7 months). Pharmacodynamic studies showed preliminary evidence of ATR inhibition and enhanced DNA double-stranded breaks in response to the combination. Conclusion To our knowledge, this report is the first of an ATR inhibitor-chemotherapy combination. The maximum dose of topotecan plus M6620 is tolerable. The combination seems particularly active in platinum-refractory small-cell lung cancer, which tends not to respond to topotecan alone. Phase II studies with biomarker evaluation are ongoing." @default.
• W2775990711 created "2018-01-05" @default.
• W2775990711 creator A5005004302 @default.
• W2775990711 creator A5005484119 @default.
• W2775990711 creator A5008933680 @default.
• W2775990711 creator A5009327463 @default.
• W2775990711 creator A5013592290 @default.
• W2775990711 creator A5015342151 @default.
• W2775990711 creator A5020366697 @default.
• W2775990711 creator A5020575293 @default.
• W2775990711 creator A5021095127 @default.
• W2775990711 creator A5026706379 @default.
• W2775990711 creator A5029070074 @default.
• W2775990711 creator A5029872582 @default.
• W2775990711 creator A5039668404 @default.
• W2775990711 creator A5040289016 @default.
• W2775990711 creator A5041200743 @default.
• W2775990711 creator A5042114293 @default.
• W2775990711 creator A5044239219 @default.
• W2775990711 creator A5045977241 @default.
• W2775990711 creator A5059147004 @default.
• W2775990711 creator A5060502925 @default.
• W2775990711 creator A5074644543 @default.
• W2775990711 creator A5083000419 @default.
• W2775990711 creator A5085215477 @default.
• W2775990711 creator A5090468019 @default.
• W2775990711 date "2018-06-01" @default.
• W2775990711 modified "2023-10-16" @default.
• W2775990711 title "Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors" @default.
• W2775990711 cites W1564224574 @default.
• W2775990711 cites W1969310368 @default.
• W2775990711 cites W1969885393 @default.
• W2775990711 cites W1983550104 @default.
• W2775990711 cites W1992443529 @default.
• W2775990711 cites W1999402226 @default.
• W2775990711 cites W2002480651 @default.
• W2775990711 cites W2013895149 @default.
• W2775990711 cites W2019219567 @default.
• W2775990711 cites W2022529631 @default.
• W2775990711 cites W2040860750 @default.
• W2775990711 cites W2050128145 @default.
• W2775990711 cites W2065434335 @default.
• W2775990711 cites W2092536432 @default.
• W2775990711 cites W2109637301 @default.
• W2775990711 cites W2131428591 @default.
• W2775990711 cites W2132089894 @default.
• W2775990711 cites W2145264022 @default.
• W2775990711 cites W2146274229 @default.
• W2775990711 cites W2148676049 @default.
• W2775990711 cites W2160738354 @default.
• W2775990711 cites W2171972386 @default.
• W2775990711 cites W2177543823 @default.
• W2775990711 cites W2177777322 @default.
• W2775990711 cites W2320341074 @default.
• W2775990711 cites W2468369037 @default.
• W2775990711 cites W2562712448 @default.
• W2775990711 cites W2563490856 @default.
• W2775990711 cites W2579136823 @default.
• W2775990711 cites W2734679460 @default.
• W2775990711 cites W2736195686 @default.
• W2775990711 cites W2750328162 @default.
• W2775990711 doi "https://doi.org/10.1200/jco.2017.76.6915" @default.
• W2775990711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5978471" @default.
• W2775990711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29252124" @default.
• W2775990711 hasPublicationYear "2018" @default.
• W2775990711 type Work @default.
• W2775990711 sameAs 2775990711 @default.
• W2775990711 citedByCount "109" @default.
• W2775990711 countsByYear W27759907112018 @default.
• W2775990711 countsByYear W27759907112019 @default.
• W2775990711 countsByYear W27759907112020 @default.
• W2775990711 countsByYear W27759907112021 @default.
• W2775990711 countsByYear W27759907112022 @default.
• W2775990711 countsByYear W27759907112023 @default.
• W2775990711 crossrefType "journal-article" @default.
• W2775990711 hasAuthorship W2775990711A5005004302 @default.
• W2775990711 hasAuthorship W2775990711A5005484119 @default.
• W2775990711 hasAuthorship W2775990711A5008933680 @default.
• W2775990711 hasAuthorship W2775990711A5009327463 @default.
• W2775990711 hasAuthorship W2775990711A5013592290 @default.
• W2775990711 hasAuthorship W2775990711A5015342151 @default.
• W2775990711 hasAuthorship W2775990711A5020366697 @default.
• W2775990711 hasAuthorship W2775990711A5020575293 @default.
• W2775990711 hasAuthorship W2775990711A5021095127 @default.
• W2775990711 hasAuthorship W2775990711A5026706379 @default.
• W2775990711 hasAuthorship W2775990711A5029070074 @default.
• W2775990711 hasAuthorship W2775990711A5029872582 @default.
• W2775990711 hasAuthorship W2775990711A5039668404 @default.
• W2775990711 hasAuthorship W2775990711A5040289016 @default.
• W2775990711 hasAuthorship W2775990711A5041200743 @default.
• W2775990711 hasAuthorship W2775990711A5042114293 @default.
• W2775990711 hasAuthorship W2775990711A5044239219 @default.
• W2775990711 hasAuthorship W2775990711A5045977241 @default.
• W2775990711 hasAuthorship W2775990711A5059147004 @default.
• W2775990711 hasAuthorship W2775990711A5060502925 @default.
• W2775990711 hasAuthorship W2775990711A5074644543 @default.
• W2775990711 hasAuthorship W2775990711A5083000419 @default.
• W2775990711 hasAuthorship W2775990711A5085215477 @default.

• next